Search Results

Concentrations in Portal Venous Blood as a Possible Mechanism for Microbiota Effects on the Immune System, and Western Diseases Published date November 20, 2023 Abstract "We show that the gut bacterial metabolites, short pro-inflammatory immune cells may travel to tissues such as the brain, the lung, the kidney etc and promote disease lifestyle diseases, most of which are immune based, in tissues remote from the gut." Authors Quanbo Wang , Charles R Mackay Tags Gut microbiota , Western lifestyle diseases , portal vein

and Genetic Preclinical Models of Ghrelin Receptor Functional Selectivity to Investigate Metabolic Disease GPCR biased signaling to design/develop new pharmacotherapeutics to treat reward- and metabolism-based diseases reward and its downstream dysregulation of metabolic function, particularly in response to obesogenic 'Western novel GPCR pharmacotherapies that improve efficacy and minimize side effects for diet-induced metabolic diseases

Kevin is also Director, Biomedical Innovation at The University of Western Australia (UWA) and the MTPConnect Western Australian Life Sciences Innovation Hub. Kevin Pfleger on the web LinkedIn ResearchGate Pubmed Google Scholar University of Western Australia

"Background: Neuroinflammation is a widely studied phenomenon underlying various neurodegenerative diseases -24 h, brains were collected for the analysis of gene expression by RT-PCR or protein expression by western Microglial activation was assessed by western blotting and immunohistochemistry.

Published date December 8, 2023 Abstract " Background: Acute respiratory distress syndrome (ARDS) is a disease In vitro, qRT‒PCR, immunofluorescence staining, and western blotting were used to determine the dynamic Western blotting and flow cytometry were used to evaluate apoptosis and reactive oxygen species (ROS)

Ph.D. from UFMG in 2006 and, after that, she performed her postdoctorate studies at the University of Western were shown to be very effective to rescue the cell death observed in a mouse model of Huntington’s disease

where he remained until 2018 studying GPCRs and their signaling pathways in the liver and in liver disease In 2018, he moved to Harrington Discovery Institute and Case Western Reserve University, where he studies

where he remained until 2018 studying GPCRs and their signaling pathways in the liver and in liver disease In 2018, he moved to Harrington Discovery Institute and Case Western Reserve University, where he studies

where he remained until 2018 studying GPCRs and their signaling pathways in the liver and in liver disease In 2018, he moved to Harrington Discovery Institute and Case Western Reserve University, where he studies

where he remained until 2018 studying GPCRs and their signaling pathways in the liver and in liver disease In 2018, he moved to Harrington Discovery Institute and Case Western Reserve University, where he studies

levels of GPRC5A in GFs under 1 mg/L LPS-induced GFs inflammatory state were evaluated by RT-qPCR and Western Western blotting analysis and immunofluorescence staining were used to further investigate the activation The results of RT-qPCR and Western blotting analysis showed that siGPRC5A (0.27±0.03, 0.71±0.00) suppressed Western blotting analysis showed that the levels of p65 and IκBα protein phosphorylation in the LPS group

News < GPCRs in Oncology and Immunology GPCRs and fibroblast heterogeneity in fibroblast-associated diseases About one-third of the commercially available drugs for various diseases target the GPCRs. Understanding the dynamics of GPCR signaling in fibroblasts with disease progression can help in the recognition of the complex interplay of different GPCR subtypes in fibroblast-mediated diseases. Apar K Ganti , Surinder K Batra , Maneesh Jain Tags GPCR signaling , fibroblast behavior , fibrotic diseases

her Ph.D. in Molecular Endocrinology being awarded in 2002 with Distinction from the University of Western cellular mechanisms by which mutations in a chloride-proton antiporter cause the renal disorder Dent’s disease

Elva moved to Canada where she obtained her Ph.D. at the University of Western Ontario, working on the

years at the Cleveland Institute of Art, he earned degrees in Biochemistry and Chemistry from Case Western

Retreat Program < Back to schedule Cannabinoid compounds to augment L-DOPA treatment in Parkinson's Disease

Immunology CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment of Inflammatory Diseases This pathway is implicated in mechanisms related to many diseases, such as cancer, psoriasis, multiple This review highlights the potential as a therapeutic target of the CCR6 receptor in numerous diseases

Severity About Amr Mousa "I am currently a Ph.D. student at the Schulich School of Medicine and Dentistry, Western Investigator Transdisciplinary Research Award (2022-2023 and 2023-2024) from the bone and joint institute, Western

and Immunology Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases receptor 2 (CXCR2) is G protein-coupled receptor (GPCR) and plays important roles in various inflammatory diseases and cancers, including chronic obstructive pulmonary disease (COPD), atherosclerosis, asthma, and pancreatic a new target for diabetes and that CXCR2 antagonists may also attenuate lung injury in coronavirus disease (COPD) , Coronavirus disease 2019 (COVID-19) , Inflammatory disease.

her Ph.D. in Molecular Endocrinology being awarded in 2002 with Distinction from the University of Western

Program < Back to schedule Biased agonism at the GLP-1 receptor: from structure to animal models of disease

< GPCR News < GPCRs in Oncology and Immunology Deciphering the genetic landscape of lumpy skin disease through comprehensive genome sequence analysis in India Published date May 23, 2024 Abstract "Lumpy Skin Disease (LSD), a poxvirus disease affecting cattle, emerged in India in 2019 and intensified in 2022, resulting , V Gairola, D Poloju, S Gulzar, K P Singh, R K Singh, G K Sharma Tags Genome sequence , Lumpy skin disease

Sponsors GPCR Retreat Program < Back to schedule Genetic Deletion of Atypical VGLUT3 Rescues Huntington’s Disease coupled receptors and their role in neurodegenerative disorders, including Alzheimer's and Huntington's diseases

Neuroimmune interplay during type 2 inflammation: symptoms, mechanisms and therapeutic targets in atopic diseases The consequences of altered neuroimmune activity differ with tissue type and disease and include: skin neuroimmune interactions that underlie the various sensory and autonomic pathologies in type 2 inflammatory diseases in targeted treatment approaches to reduce type 2 inflammation and its associated symptoms in these diseases CSU , Calcitonin gene-related peptide , Chronic idiopathic urticaria , Chronic obstructive pulmonary disease

pro-inflammatory phenotype of VSMCs was measured by phagocytic activity assays, adhesion assay and Western

reaction networks are an important and emerging tool for the study of cell signaling networks involved in disease One promising potential application of such mathematical models is the study of how disease-causing mutations promote the signaling phenotype that contributes to the disease. and use model-driven explorations to uncover and explore multiple new areas for investigating this disease revealed the potential for previously unknown qualitative differences between seemingly interchangeable disease-promoting

However, the physiological functions of many GPCRs and the involvement of them in autoimmune diseases However, Gpr141 deficiency exacerbated disease conditions of experimental autoimmune encephalomyelitis , an autoimmune disease model for multiple sclerosis, with increased inflammation in the spinal cord. that targeting GPR141 may be a possible therapeutic intervention for modulating chronic inflammatory diseases Okazaki, Akira Nakamura, Ryo Goitsuka, Tomonori Kaifu Tags G protein–coupled receptor 141 , autoimmune disease

Indian Institute of Science, Bangalore, India, to investigate the mechanisms behind rare mitochondrial diseases at the Cleveland Clinic in Ohio, USA, studying the gut microbiome and its impact on cardiovascular disease gut microbe-derived metabolite called phenylacetylglutamine (PAG), which is linked to cardiovascular disease as targets for more than one-third of all prescribed drugs currently used in the treatment of human diseases